Advanced Acral Melanoma Therapies: Current Status and Future Directions

Lv J, Dai B, Kong Y, Shen X, Kong J. Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6:31432.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166(17):1907–14.

PubMed  Article  Google Scholar 

Shaw JH, Koea JB. Acral (volar-subungual) melanoma in Auckland. New Zealand. Br J Surg. 1988;75(1):69–72.

CAS  PubMed  Google Scholar 

Cascinelli N, Zurrida S, Galimberti V, Bartoli C, Bufalino R, Del Prato I, Mascheroni L, Testori A, Clemente C. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol. 1994;20(12):817–22.

CAS  PubMed  Article  Google Scholar 

Ridgeway CA, Hieken TJ, Ronan SG, Kim DK, Das Gupta TK. Acral lentiginous melanoma. Arch Surg. 1995;130(1):88–92.

CAS  PubMed  Article  Google Scholar 

Chang JW. Acral melanoma: a unique disease in Asia. JAMA Dermatol. 2013;149(11):1272–3.

PubMed  Article  Google Scholar 

Hudson DA, Krige JE. Melanoma in black South Africans. J Am Coll Surg. 1995;180(1):65–71.

CAS  PubMed  Google Scholar 

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–66.

CAS  PubMed  Article  Google Scholar 

Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16(5):1743–51.

CAS  PubMed  Article  Google Scholar 

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22(6):1118–25.

CAS  PubMed  Article  Google Scholar 

Yi JH, Yi SY, Lee HR, Lee SI, Lim DH, Kim JH, Park KW, Lee J. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia. Melanoma Res. 2011;21(3):223–7.

CAS  PubMed  Article  Google Scholar 

Guo YQ, Ding Y, Li DD, Li JJ, Peng RQ, Wen XZ, Zhang X, Zhang XS. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. Med Oncol. 2015;32(9):234.

PubMed  Article  CAS  Google Scholar 

Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 2020;57(3):609–18.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, et al. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

CAS  PubMed  Article  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017;23:3484–8.

CAS  PubMed  Article  Google Scholar 

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354–62.

CAS  PubMed  Article  Google Scholar 

•• Zheng Q, Li J, Zhang H, Wang Y, Zhang S. Immune checkpoint inhibitors in advanced acral melanoma: a systematic review. Front Oncol. 2020;10:602705. This reference is of outstanding importance because it systematically analyzes the therapeutic effects and safety profile of ICI treatments in advanced AM, and paves the way for further research on the treatment of advanced AM.

Saberian C, Ludford K, Roszik J, Gruschkus S, Johnson DH, Bernatchez C, et al. Analysis of tumor mutation burden (TMB), PD-L1 status and clinical outcomes with checkpoint inhibitors (CPI) in acral melanoma (AM). Pigment Cell Melanoma Res. 2020;33(1):226–7.

Google Scholar 

Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical activity of ipilimumab in acral melanoma: a retrospective review. Oncologist. 2015;20(6):648–52.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yamazaki N, Kiyohara Y, Uhara H, Tsuchida T, Maruyama K, Shakunaga N, Itakura E, Komoto A. Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: a postmarketing surveillance. J Dermatol. 2020;47(8):834–48.

CAS  PubMed  PubMed Central  Article  Google Scholar 

van Not OJ, de Meza MM, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van Breeschoten J, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Bonenkamp HJ, Boers-Sonderen MJ, et al. Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study. Eur J Cancer. 2022;167:70–80.

PubMed  Article  CAS  Google Scholar 

Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Mao L, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Diede SJ, Zhou Y, Ge J, Li J, Wu H, Guo J. A phase Ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151). Transl Oncol. 2019;12(6):828–35.

PubMed  PubMed Central  Article  Google Scholar 

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168–78.

CAS  PubMed  Article  Google Scholar 

Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res. 2020;26(16):4250–9.

CAS  PubMed  Article  Google Scholar 

Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I. Clinical and genetic analysis of melanomas arising in acral sites. Eur J Cancer. 2019;119:66–76.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019;12(1):7.

PubMed  PubMed Central  Article  Google Scholar 

• Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020;31(9):1198–206. This reference is of importance because it clearly shows that the objective response to anti-PD-1 treatment in AM patients is significantly affected by primary tumor location.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

CAS  PubMed  Article  Google Scholar 

Hughes T, Coffin RS, Lilley CE, Ponce R, Kaufman HL. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virother. 2014;3:11–20.

PubMed  PubMed Central  Google Scholar 

Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.

PubMed  PubMed Central  Article  Google Scholar 

Franke V, Smeets PMG, van der Wal JE, van Akkooi ACJ. Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma. Melanoma Res. 2020;30:548–51.

CAS  PubMed  Article  Google Scholar 

• Cui C, Wang X, Lian B, Ji Q, Zhou L, Chi Z, Si L, Sheng X, Kong Y, Yu J, Li S, Mao L, Tang B, Dai J, Yan X, Bai X, Andtbacka R, Guo J. OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study. J Immunother Cancer. 2022;10(4):e004307. This reference is of importance because it clearly shows that OrienX010 oncolytic virotherapy has a tolerable safety profile with antitumor effects in both injected and non-injected metastases and warrants further evaluation in patients with acral melanoma.

Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3(2):196–200.

CAS  PubMed  Article  Google Scholar 

Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, Konishi T, Comin-Anduix B, Dauphine C, Vargas HI, Economou JS, Ribas A, Bruhn KW, Craft N. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol. 2012;132(1):163–9.

CAS  PubMed  Article 

留言 (0)

沒有登入
gif